Navigation Links
Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010

NEWTON, Mass., Aug. 5 /PRNewswire-FirstCall/ -- Microfluidics International Corporation (OTC Bulletin Board: MFLU) announced today the Company will release second quarter 2010 financial results on Tuesday, August 10, 2010, at 8:30am ET.

(Logo: )

(Logo: )

Michael C. Ferrara, President and Chief Executive Officer, and Peter F. Byczko, Vice President of Finance and Chief Accounting Officer, will host a conference call and live audio webcast.

Participants are invited to attend the call by visiting and clicking on the webcast link, or by dialing 866.730.5767 (within the United States) or +1 857.350.1591 (outside the United States). The passcode is 17982013.

A replay will be available for one week beginning approximately two hours after the live call. To access the replay, dial 888.286.8010 (within the United States) or +1 617.801.6888 (outside the United States). The passcode is 45623626.


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these statements by the fact that they use words such as "anticipate," "believe," "estimate," "expect," "intend," "project," "plan," "outlook," and other words and terms of similar meaning. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Among the factors that could cause actual results and outcomes to differ materially from those contained in such forward-looking statements are the following: our ability to access sufficient working capital, including a new working capital line; our continued compliance with the representations, warranties and covenants under our existing convertible debenture and revolving line of credit; our history of losses, which includes net losses in four of the last five fiscal years; the timing and size of customer orders for our products; the adoption, timing and performance of new technology and products developed by us; changes and advances in technology that may make our products obsolete or reduce demand for our products; our ability to protect and maintain the confidentiality of our intellectual property; our ability to retain key employees and our reliance on a new management team; changes in governmental rules and regulations, including health care and those regulating the exportation of goods; and general economic and business conditions, including those adversely effecting the pharmaceutical and biotechnology industries. For a more detailed discussion of risks and uncertainties which could cause actual results to differ from those contained in our forward-looking statements, see Item 1A, "Risk Factors" in our annual report on Form 10-K and our other periodic reports filed with the SEC. You should not place undue reliance on our forward-looking statements, which speak only as of the date they are made. We are providing this information as of this date, and we do not undertake to update the information included in this presentation, whether as a result of new information, future events or otherwise.


Microfluidics International Corporation (OTC Bulletin Board: MFLU) is the exclusive producer of Microfluidizer® high shear fluid processors for uniform particle size reduction, robust cell disruption and bottom-up nanoparticle creation. Used primarily by pharmaceutical, biotechnology, chemical, cosmetic, nutraceutical/food and energy companies to research, develop and improve products with efficient processes, more than 3,000 Microfluidizer processors are installed at customer sites in 50 countries around the world. The innovative Microfluidics Technology Center, located at the company's headquarters outside Boston, Mass., is staffed by expert engineers with a wide range of nanotechnology and application experience for Proof of Concept and Process Development services.

By producing smaller particle sizes and a more narrow distribution than other technologies, with scaleup from lab to production guaranteed, Microfluidics enables companies to create tiny particles that achieve big results. To learn more, visit

SOURCE Microfluidics International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Microfluidics Announces Two New Board Members
2. Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results
3. Microfluidics International Corporation to Report Fourth Quarter and Year-end 2009 Financial Results on February 23, 2010
4. Microfluidics Enters into Exclusive Partnership with ATS Scientific to Expand Distribution in Canada
5. Chindex International to Report First Quarter 2011 Financial Results
6. Robert F. Walters Appointed Chairman of the Board of Directors of ORBIS International
7. Airline Passenger Experience Association Teams Up With ORBIS International in Their Fight Against Avoidable Blindness
8. Update: International HIV/AIDS Partnership Wins Two Awards for Supply Chain Excellence
9. New Edition of Guidelines for Involving Communities in HIV Prevention Research Released at International AIDS Conference
10. SRI International and Stanford University School of Medicines MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices
11. Encorium Group, Inc. Acquires Progenitor International Research, a Vaccine Focused Emerging Market CRO
Post Your Comments:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
Breaking Medicine News(10 mins):